Unstimulated neutrophils inhibited activation and recruitment of thrombin-or collagen-stimulated platelets in an agonist-specific manner. This occurred under conditions of close physical cell-cell contact, although biochemical adhesion between the cells as mediated by P-selectin was not required. Moreover, in the presence of monoclonal P-selectin antibodies that blocked biochemical platelet-neutrophil adhesion, thrombin-stimulated platelets were more efficiently downregulated by neutrophils. This suggested a prothrombotic role for P-selectin under these circumstances. The neutrophil downregulatory effect on thrombin-stimulated platelets was amplified by lipoxygenase inhibition with 5,8,11,14-eicosatetraynoic acid. In contrast, the neutrophil inhibitory effect on platelets was markedly reduced by platelet-derived 12S-hydroxy-5,8-cis, 10-trans, 14-cis-eicosatetraenoic acid (12S-HETE), as well as by the platelet-neutrophil transcellular product, 12S,20-dihydroxy-5,8,10,14-eicosatetraenoic acid (12S,20-DiHETE), but not by another comparable metabolite, 5S,12S-dihydroxy-6-trans, 8-cis, 10-trans, 14-cis-eicosatetraenoic acid (5S,12S-DiHETE), or the neutrophil-derived hydroxy acid leukotriene B4. The neutrophil downregulatory effect on thrombin-induced platelet reactivity was enhanced by aspirin treatment. This may represent a novel action of aspirin as an inhibitor of platelet function. These results provide in vitro biochemical and functional evidence for the thromboregulatory role of neutrophils and emphasize the multicellular aspect of hemostasis and thrombosis. (J. Clin.
Introduction
Platelets and neutrophils are brought into proximity in a variety of circumstances during hemostasis, thrombosis, and the inflammatory response. Both cell types can modulate each others' reactivity by virtue of physical contact per se and biochemical interactions.
Platelets or released products therefrom can modify the functional responsiveness of neutrophils, including such functions as chemotaxis, adhesion, aggregation, and release of neutrophil granule constituents (1) . The complexities involved in studying effects of neutrophils on platelets are emphasized by recent contradictory reports in the literature. These range from neutrophil promotion of platelet reactivity (2) (3) (4) (5) to neutrophil blockage of platelet responsiveness (6) (7) (8) (9) (10) (11) (12) . The reasons for these differences are not completely understood, but must in part be attributable to methodology. This would include cell preparation, specific type and concentration ofagonist, and use ofeither intact neutrophils or releasates derived therefrom ( 1 ).
We initiated a detailed study ofplatelet-neutrophil interactions as part of our interest in early cellular and biochemical events in thrombosis. The experimental system used allows for independent evaluation of platelet activation and recruitment as influenced by intact unstimulated neutrophils under conditions ofclose cell contact for a brieftime interval. It was demonstrated that human neutrophils markedly decreased human platelet activation (serotonin release) and recruitment (proaggregatory activity ofcell-free releasates) induced by collagen or thrombin.
Materials and Methods
Blood collection, platelet processing, and labeling. 240 ml ofblood was collected by free flow in plastic tubing through a 15-gauge needle into 50-ml polypropylene tubes (13) (14) (15) . One tube contained 4.5 ml of 3.8% sodium citrate in a total volume of45 ml. Five others contained 6 ml of acid-citrate-dextrose (ACD' (mM): 38 citric acid, 75 sodium citrate, and 135 glucose) in a total volume of 46 ml. Blood was centrifuged at 200 g to obtain platelet-rich plasma (PRP). The PRP tube prepared with citrate (adjusted to a platelet count of 4-5 X 108/ml with platelet-poor plasma) was capped and maintained at 220C under 5% C02-air, for use as assay system for platelet aggregation (13) (14) (15) .
The PRP from the ACD-anticoagulated tubes was used to prepare ['4C]serotonin (5-HT)-labeled washed platelets for use in the activation system (13, 14) . Radiolabeled serotonin ([ 4C] 5-HT) creatinine sulfate, 54 mCi/mmol (in 2% ethanol) was obtained from Amersham Corp. (Arlington Heights, IL). 0.4 nmol was added per ml PRP and the tube was mixed gently and left at room temperature for 60 min under 5% C02-air. The tube was inverted and placed under C02-air once again during this interval. Uptake (average 96%) was measured by counting 50 ML ofPRP for radioactivity compared with 50 d ofplateletpoor plasma. Platelets were then washed as previously described (13) (14) (15) and finally suspended in cold 0.9% NaCl adjusted to 109/ml. Imipramine (2.5 MM final concentration) was added 1 min before the ago-1. Abbreviations used in this paper: ACD, 38 mM citric acid, 75 mM sodium citrate, 135 mM glucose; ASA, acetylsalicylic acid; DFP, diisopropyl fluorophosphate; 12S,20-DiHETE, 12S,20-dihydroxy-5,8, 10, 14-eicosatetraenoic acid; 5S, 12S-DiHETE, 5S, 12S-dihydroxy-6-trans,8-cis, O-trans, 14-cis-eicosatetraenoic acid; EDRF/NO, endothelium-derived relaxing factor/nitric oxide; ETYA, 5,8,11,14-eicosatenist to prevent reuptake ofreleased 5-HT. Activation was quantified as total released radioactivity by counting 50 ,ul cell-free releasate (see below) in 4 ml Aquasol-2 (DuPont NEN Research Products, Boston, MA).
Preparation ofneutrophil suspensions. The remaining blood sample in the ACD-anticoagulated tubes (after removal of PRP) was used for neutrophil preparation. This was accomplished by Dextran T500 sedimentation and subsequent centrifugation through Ficoll-Hypaque (d 1.077), aspreviouslydescribed ( 15) . To ensure removal ofhemoglobin after the erythrocyte lysis step, an additional wash of the neutrophils was carried out by resuspension in buffer and centrifugation. The surface of the pellet was then rinsed three times with saline. Neutrophils were finally resuspended in Hepes buffer ( Systemfor independent evaluation ofplatelet activation and recruitment. The two-stage in vitro system used ( Fig. 1) has been previously described in studieswith combined suspensions ofplatelets and erythrocytes ( 13, 14) . In the present study, the phosphate-buffered saline was PREINCUBATE PLAl PLATELETS + NEU1
THEN ADD AGC substituted with Hepes buffer (above) in the generating system ( 13) . Platelets (2 X 108/ml) or platelets plus neutrophils (0.5-30 X 106/ml) in a total volume of0.5 ml, (Ca2" conc. 1 mM), were preincubated for 10 min at 370C, stimulated with collagen or thrombin, mixed by inverting three times, and centrifuged (50 s, 13,000 g Sigma. N0-Methyl-L-arginine (500 gM) was from Calbiochem (La Jolla, CA). FeSO4 (20 MM) was from Fisher (Pittsburgh, PA). All reagents were present during the preincubation period, except NGmethyl-L-arginine, which was previously incubated with the neutrophils for 60 min. Hemoglobin was prepared by treatment with sodium dithionite ( 10-fold excess), dialysis against water (3 changes in 2 h), and storage in aliquots at -70°C. After thawing, the hemoglobin was oxygenated under a stream of oxygen and centrifuged at 13,000 g (2 min) to remove solids. Diisopropyl fluorophosphate (DFP) treatment of neutrophils was performed as previously described ( 15) .
The murine monoclonal anti-P-selectin antibodies used were as follows: AC1.2 and GE12 (17) and G1, S-12, and W-40 (18) (19) (20) (21) . All antibodies were present during the 10-min preincubation period at a concentration of 10-15 Mg/ml. Effects ofagonist concentration. Addition ofcollagen to a combined suspension of human platelets and neutrophils (1 min) resulted in a releasate ( 13) that demonstrated decreased platelet reactivity when compared with a releasate obtained from stimulated platelets alone (Fig. 1, A and B) . When the dose of collagen was increased from 1 to 16 ,g/ml, neutrophil inhibition of platelet 5-HT release (activation) relative to platelets alone varied from 46 to 36% (Fig. 1 A) . When the collagen-induced cell-free releasate was used as agonist to induce platelet recruitment in PRP ( 13), neutrophil-induced inhibition was pronounced ( Fig. 1 B) . Addition ofthrombin to combined suspensions of platelets and neutrophils also resulted in a releasate with reduced 5-HT content, compared with releasates from platelets alone (Fig. 1  C ). An increase in dose from 0.1 to I U/ml thrombin decreased the percentage ofneutrophil inhibition of 5-HT release from 87 to 43% (Fig. 1 C) . As with collagen, thrombin-induced platelet recruitment was lower in the presence of neutrophils (Fig. I D) . Inhibition ofplatelet reactivity by neutrophils demonstrated a steeper dose-response relationship for thrombin than collagen.
Effects of neutrophil number. Inhibition of platelet 5-HT release induced by collagen occurred at low concentrations of neutrophils (0.5 x 106/ml) and plateaued in the physiological range (4-8 x 106/ml) ( Fig. 2 A) . The same phenomenon was observed when neutrophils inhibited platelet recruitment (Fig.  2 B) . In addition to the washed system, neutrophils (4 x 106/ ml) also inhibited platelet reactivity in platelet-rich plasma, stimulated by 16 ,g/ml collagen (41.1±0.9% 5-HT release vs.
53.2±1.7% with PRP alone, mean±SEM, P < 0.01). Platelet recruitment by cell-free supernates derived from PRP or PRP plus neutrophils also indicated neutrophil inhibition ofplatelet reactivity (PRP + neutrophils: 47.0+7.6 mm; PRP alone: In contrast to collagen, neutrophil-dependent inhibition of platelet activation with thrombin became significant at neutrophil concentrations in the physiological range. The inhibitory effect of neutrophils on thrombin-stimulated suspensions was highly dependent on neutrophil concentration (Fig. 2 C) . Neutrophil inhibition of platelet recruitment by thrombin-elicited cell-free releasates demonstrated a similar dependence on neutrophil number (Fig. 2 D) .
Eicosanoid participation in inhibition ofplatelet activation by neutrophils
Platelet eicosanoids such as TXA2 are rapidly released upon stimulation, and may have initiated the neutrophil inhibitory activity. This possibility was tested by pretreating platelets alone or platelet-neutrophil mixtures with aspirin during the preincubation period. With collagen, inhibition of platelet 5-HT release by 4 X 106 neutrophils/ml was reduced by aspirin treatment (Fig. 3 A) . However, with higher numbers ofneutrophils in the acetylsalicylic acid (ASA)-treated system, neutrophil inhibition of platelet activation induced by collagen was marked at 8 x 106 and 16 X 106 neutrophils/ml (Table I) .
In contrast to collagen, when the cells were stimulated with thrombin, neutrophil inhibition of platelet reactivity became far more effective after ASA-treatment (Fig. 3 C) . This inhibition was even more pronounced at higher neutrophil concentrations (Table I) .
To extend the data obtained with the cyclooxygenase inhibitor ASA, we inhibited both cyclooxygenase and lipoxygenase with ETYA. In this instance as well, neutrophil inhibition of platelet 5-HT release (activation) was reduced with collagen as stimulus, but was potentiated with thrombin ( Fig. 3) . Results ofexperiments on recruitment in the setting ofeicosanoid inhibition followed the same pattern as those described for activation (Fig. 3 B, D) .
Using [3H] arachidonate-labeled platelets in our activation-recruitment system (Fig. 1) , we previously reported ( 13) that aspirin treatment ofplatelets alone resulted in a paradoxical reduction of 12S-HETE synthesis. This occurred during the short (< 1 min) time interval studied (13) . The reduction in 12S-HETE was greater with thrombin (81%) than collagen (42%) (13) . We interpret the data depicted in Fig. 3, C (Table II) . In sharp contrast, with thrombin, the 12-lipoxygenase products 12S-HETE and 12S,20-Di-HETE, but not neutrophil 5-lipoxygenase metabolites, reduced the neutrophil inhibitory effect (Table II) . These results support the concept that 12-lipoxygenase products reduce inhibition of thrombin-activated platelets by neutrophils.
Effects ofenzymatic removal ofreleased platelet ADP We examined possible participation of neutrophil ecto-ADPase(s) activity (24, 25) in neutrophil inhibition of platelet reactivity. Platelets alone or platelet-neutrophil suspensions were stimulated in the presence or absence of the ADPase, apyrase (2 U/ml). With platelets alone, apyrase reduced 5-HT release in collagen-, but not in thrombin-stimulated samples (Fig. 4) . This indicated that under these conditions, removal of released platelet ADP reduced collagen-induced 5-HT release (Fig. 4 , bar a vs. c), but did not significantly inhibit thrombininduced 5-HT release (Fig. 4, bar a' vs. c'). Therefore, with thrombin, the inhibitory effect of neutrophils did not result from neutrophil ecto-ADPase. This is shown in Fig. 4 where with thrombin, neutrophils eliminated a total of 41% 5-HT release (bar a' minus bar b'), which was paralleled by a decrease of42% 5-HT release due to non-ADP-dependent mechanisms (bar c' minus bar d').
However, similar calculations with collagen as agonist, assuming that ADP-dependent and non-ADP-dependent 5-HT release are additive, indicate a possible contribution ofneutrophil ADPase. Here, the neutrophil inhibitory effect results in a loss of 34% 5-HT release (bar a minus bar b), whereas non-ADP-dependent mechanisms cause a decrease of only 24% 5-HT release (bar c minus bar d). The difference, a loss of 10% 5-HT release, is likely due to removal of released platelet ADP by neutrophil ecto-ADPase. The fraction ofthe total inhibitory effect potentially related to neutrophil ecto-ADPase ( 10/34 or 29%) is therefore significant in the case of collagen, although not the major cause of neutrophil-dependent inhibition of platelet reactivity in this experimental setting. Neutrophil inhibition ofplatelet reactivity is independent of EDRF/NO synthesis or serine protease activity
Neutrophils have been reported to produce EDRF/NO (26-28), which can inhibit platelet responsiveness (9-12). We therefore evaluated effects of compounds known to modulate NO formation and/or activity ( 16) . Platelets or platelet-neutrophil suspensions, either ASA treated or untreated, were stimulated with collagen (16 Ig/ml) or thrombin ( 1.0 U/ml). This was done in the presence or absence ofSOD, L-arginine, hemoglobin, FeSO4, NG-methyl-L-arginine, and L-arginine plus N0-methyl-L-arginine (data not shown). These pharmacologic modulators of EDRF/NO caused no variations in 5-HT release and therefore no changes in the neutrophil inhibitory effect on platelet activation under these conditions. Thus, in our activation-recruitment system, NO does not account for the neutrophil inhibitory effect on platelet reactivity. Activated neutrophils release serine protease(s) that can modify platelet function. Although we were working with unstimulated PMN, we treated neutrophils with the cell-penetrating serine protease inhibitor, DFP. DFP-treated and -untreated neutrophils in combined suspension with platelets in the activation system were compared. Neutrophil inhibition ofplatelet activation was unaffected by DFP treatment (data not shown). Therefore, with unstimulated neutrophils, the inhibition of platelet activation was not mediated by serine proteases. P-selectin-dependent platelet-neutrophil adhesion limits neutrophil inhibition ofplatelet reactivity P-selectin [platelet activation-dependent granule-external membrane protein (29) (PADGEM), a granule membrane protein ofMr 140,000 (30) (GMP-140), CD 62] belongs to the selectin family of adhesive proteins (29) (30) (31) . P-selectin mediates adhesion of activated platelets to neutrophils and monocytes ( 17, 20, 21, (32) (33) (34) and subsets oflymphocytes (35) . We used specific murine monoclonal anti-P-selectin antibodies to determine whether a P-selectin-mediated platelet-neutrophil adhesion step was required for neutrophil inhibition ofplatelet reactivity. The antibodies GE 12 (17) and G 1 (20, 21 ) inhibit P-selectin-mediated neutrophil adhesion (30) . Control anti-P-selectin antibodies AC1.2 (17), S12 (20, 21 ) , and W40 (18) do not inhibit platelet-neutrophil adhesion.
Antibodies GE12 or GI had no effect on the activation of platelets alone (Figs. 5 and 6 ). However, in the presence of these antibodies (which inhibit platelet-neutrophil adhesion), the neutrophil inhibitory effect on platelet activation was actually enhanced. This enhancement was more pronounced in thrombin-than in collagen-stimulated cell mixtures. With collagen as agonist, neutrophil-dependent platelet inhibition increased from 61 to 68%. The percentage inhibition was calculated as 5-HT released by: 100 X [(platelets alone -platelets plus neutrophils)/platelets alone]. Similarly in the presence of G1, platelet inhibition by neutrophils increased from 40 to 56%. With thrombin, this trend was even more obvious. Neutrophil-dependent platelet inhibition rose from 67 to 90% upon addition ofGE 12, and from 23 to 52% with Gl (Figs. 5 and 6 ). The enhancing effect ofthese antibodies is even more apparent if 5-HT release of platelet-neutrophil mixtures in the absence and presence of adhesion-blocking antibodies is compared. If 5-HT release in the absence ofthese antibodies is considered to be 100%, then with collagen as agonist, inhibition increased over controls by 22 and 24% with GE12 and G 1, respectively. Blocking Non-Blocking Figure 5 . A specific monoclonal antibody against P-selectin, which inhibits platelet-neutrophil adhesion (GE12), enhances neutrophil inhibition of platelet activation (5-HT release), whereas a different specific monoclonal antibody against P-selectin, which does not inhibit platelet-neutrophil adhesion (ACI.2), was without effect. Platelets alone (2 x 108/ml) (in) or platelets plus neutrophils (8 x 106/ml) (n) were stimulated with collagen or thrombin. Results are mean±SEM of paired samples (n = 8); *P < 0.001 for both the comparison of platelets plus neutrophils between GE12 and control (no antibody), as well as between antibody GE12 and antibody AC 1.2. In all cases P < 0.0001 for the difference between 5-HT release from platelets alone and from platelets plus neutrophils. No Ab G1 S12 W40
Blocking Non-/Blocking Figure 6 . Results comparable to those shown in Fig. 5 were obtained with another group of antibodies against P-selectin. Antibody GI, which inhibits adhesion between activated platelets and unstimulated neutrophils, enhances neutrophil inhibition ofplatelet activation (5-HT release). Antibodies S12 and W40, which do not inhibit platelet-neutrophil adhesion had no effect on neutrophil inhibition of platelet activation. Experimental conditions and P values are the same as for Fig. 5 .
With thrombin the inhibition increased 69 and 39%, respectively. In contrast, the monoclonal anti-P-selectin antibodies AC1.2, S12, or W40 (which do not affect platelet-neutrophil adhesion) essentially had no influence on neutrophil inhibition of platelet activation (Figs. 5 and 6 ). These data indicated that a platelet-neutrophil adhesion step was not a prerequisite for the neutrophil to block platelet reactivity. In fact inhibition was enhanced in the presence of antibodies that blocked adhesion.
Discussion
Unstimulated human neutrophils strongly downregulated human platelet responsiveness during the first minute ofstimulation by platelet agonists. This was demonstrated in an in vitro system (Fig. 1 ) , which independently evaluates platelet activation and recruitment. This method may serve as an in vitro model for early hemostatic and thrombotic events ( 13 ) . After the agonist is added, platelets and neutrophils are brought into close contact, and then the cells are removed. The supernatant fluid containing the products released from the cells is then used as a probe for platelet recruitment and tested biochemically for platelet activation. Thus, our system evaluates very early events, within 1 min of stimulation. Since platelet agonists are more likely to be available during the early phase of thrombus formation, we chose collagen and thrombin for these studies. Choice of agonist for the stimula- In agreement with our data, addition of a platelet agonist to platelet-neutrophil mixtures resulted in neutrophil inhibition of platelet reactivity (8) (9) (10) . However, with some neutrophil agonists, platelet reactivity in combined suspensions was promoted (4, 5) .
The experimental results presented herein indicate in addition that neutrophil inhibition ofplatelet reactivity induced by collagen or thrombin was stimulus specific. At similar levels of activation of platelets alone, neutrophil inhibition of 5-HT release was greater in samples stimulated with thrombin than with collagen (Fig. 1, A and C) . Furthermore, at low neutrophil concentrations, inhibition was more efficient with collagen than with thrombin (Fig. 2) . Differences between these platelet agonists were also observed in eicosanoid regulation of platelet-neutrophil interactions. At the same neutrophil number, aspirin enhanced the neutrophil effect with thrombin but reduced it with collagen (Fig. 3) . In addition, 12S-HETE had a regulatory role in thrombin-but not in collagen-stimulated samples (Table II) . Last, P-selectin antibodies, which block adhesion, had much more pronounced effects with thrombin as platelet agonist, than with collagen (Figs. 5 and 6).
Neutrophil inhibition of platelet reactivity as observed in our in vitro system could have implications for comprehension ofearly events in hemostasis and thrombosis. The data suggest that neutrophils have the capacity to modulate initiation and propagation of a developing platelet thrombus.
As mentioned above, in the setting ofaspirin treatment, the neutrophil inhibitory effect was reduced with collagen at physiological neutrophil concentrations (4 X 106/ml, Fig. 3 A) . This effect was reversed at higher neutrophil concentrations (Table I) . This suggested the presence of two mechanisms of neutrophil control: aspirin-sensitive and aspirin-insensitive. The aspirin-sensitive mechanism seems more efficient since lower quantities of neutrophils were required.
Treatment of combined platelet-neutrophil suspensions containing 4 X 106 neutrophils/ml with ETYA (inhibiting both cyclooxygenase and lipoxygenase) in samples stimulated with collagen yielded data similar to that obtained after aspirin treatment (Fig. 3 A) . This indicated that lipoxygenase metabolites were not involved in neutrophil inhibition ofplatelet reactivity in collagen-stimulated cells. The concept was verified by the inability of exogenously provided lipoxygenase products to alter neutrophil inhibition of platelet activation (Table II) .
In contrast to the above results with collagen, neutrophil inhibitory effects on platelet reactivity were enhanced after thrombin stimulation of the aspirin-treated system (Fig. 3 B) . At the 1 min time point in our activation system (Fig. 1) , aspirin treatment led to reduced 12S-HETE production ( 13) . The dual cyclooxygenase and lipoxygenase inhibitor, ETYA further depleted the quantity of 12S-HETE formed. In this instance, neutrophil inhibitory activity ofplatelet activation with thrombin was even further enhanced (Fig. 3 B) . It can therefore be inferred that 12-lipoxygenase metabolites reduce thrombin-induced neutrophil inhibitory activity. This, in fact, did occur when 12-lipoxygenase metabolites were exogenously added to the thrombin-stimulated system (Table II) .
Our data with thrombin provide yet another example of participation of platelet lipoxygenase metabolites in interactions involving other cell types, i.e., neutrophils (23) . Downregulation of the neutrophil inhibitory effect was not abrogated by transcellular metabolism of platelet 12S-HETE to 12S,20-Di-HETE via w-hydroxylation by unstimulated neutrophils (22) . In contrast, this property of 12S-HETE was no longer demonstrable with 5S,12S-DiHETE generated from platelet 12S-HETE via 5-lipoxygenation by stimulated neutrophils (23) (Table II) .
Since they reduce neutrophil inhibition of platelet reactivity, 12-lipoxygenase products are "prothrombotic" in thrombin-stimulated combined cell suspensions. The early ASA-induced reduction in 12-HETE formation can therefore be regarded as a beneficial effect of this compound, occurring in addition to cyclooxygenase inhibition. Furthermore, the enhancement of neutrophil inhibition in ASA-treated samples stimulated with thrombin may also be a part of the beneficial therapeutic effect of aspirin when platelet activation by thrombin occurs in vivo (Fig. 3 B) .
Several additional mechanisms could have been responsible, at least in part, for neutrophil inhibition ofplatelet reactivity as demonstrated in our system. These included neutrophil ADPase(s), serine proteases, and EDRF/NO formation. The results obtained rule out participation of neutrophil EDRF/ NO and serine proteases since no variations in 5-HT release were found in the presence or absence ofpharmacologic modulators of EDRF activity or after treatment with the cell-penetrating protease inhibitor DFP. Neutrophil ADPase activity was a factor only in samples stimulated with collagen, but not when thrombin was used as agonist. This may reflect the observations that stimulation of platelets by high doses ofthrombin does not depend on platelet-released ADP while collagen stimulation of platelets does (36) .
The fact that most of the above mechanisms were not involved in our results is probably a reflection of the following: (a) we studied unstimulated neutrophils; (b) the platelets were highly stimulated with specific agonists; (c) maximal cell contact was facilitated; and (d) duration of platelet-neutrophil contact was brief in order to simulate early in vivo thrombotic events.
Upon cell activation, the adhesive protein P-selectin is expressed on the platelet or endothelial cell surface ( 17, 30, 31 ) , where it mediates adhesion of neutrophils and monocytes. It has been suggested that P-selectin may be responsible for initial adhesion of neutrophils at sites of vascular injury, leading to leukocyte rolling (20, 37, 38) . In vivo, P-selectin may play a central role in leukocyte accumulation within thrombi (39) .
It was important to discern whether direct platelet-neutrophil adhesion was necessary for the inhibitory effect of neutrophils on platelets to occur. This was examined with specific monoclonal antibodies against P-selectin, which blocked platelet-neutrophil adhesion. The results indicated that neutrophil inhibition of platelet reactivity was actually enhanced when adhesion was blocked (Figs. 5 and 6 ). Thus, neutrophils are more effective in controlling platelet reactivity when the cells are not adherent to each other. Thus, it should be considered that P-selectin, in keeping with other platelet a-granule constituents, acts in a prothrombotic manner, via its ability to reduce neutrophil inhibition of platelet reactivity.
Two circumstances under which the efficiency of neutrophils in blocking platelet reactivity was increased included (a) when lipoxygenase metabolism was blocked by ETYA in thrombin-stimulated cell suspensions and no hydroxy acids were produced (Fig. 3) and (b) when metabolic platelet-neu-trophil adhesion was blocked by P-selectin antibodies (Figs. 5  and 6 ). With regard to (a), lipoxygenase-derived hydroxy acids have been reported to increase cell adhesion (40) , and we could reduce neutrophil-mediated inhibition ofplatelet reactivity in vitro by adding back hydroxy acids (Table II) . These compounds may have increased platelet adhesion. Thus, neutrophils may inhibit best when there is proximity, but not necessarily adhesion to stimulated platelets. We suggest that neutrophil inhibition ofplatelet reactivity may operate maximally via a fluid phase between the cells.
In conclusion, stimulation of platelets in the presence of neutrophils for 60 s results in inhibition ofplatelet reactivity. A P-selectin-induced adhesion step is not required for this downregulation mechanism. Furthermore, inhibition of P-selectininduced adhesion actually promoted neutrophil reduction of platelet responsiveness. Novel observations were made regarding participation of eicosanoid metabolites in these cell-cell interactions. The platelet 12-lipoxygenase product, 12S-HETE or its derivative, 12S,20-DiHETE, originating from transcellular metabolism between platelets and unstimulated neutrophils, reduced the inhibitory effect of neutrophils when the system was activated by thrombin. Also, aspirin treatment resulted in enhancement ofthe neutrophil downregulatory effect after thrombin stimulation. The latter represents a heretofore unrecognized potential antithrombotic effect of aspirin in the setting ofthrombin formation in vivo. Neutrophil downregulation of platelet reactivity also occurred in platelet-rich plasma, indicating physiologic significance. These results demonstrate the role of neutrophils as cellular thromboregulators and provide further evidence for the concept ofthrombosis as a multicellular process.
